NCT04279444View on ClinicalTrials.gov

Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

November 10, 2020

Study Completion Date

November 15, 2020

Conditions
Type 2 Diabetes
Interventions
DIETARY_SUPPLEMENT

BKR-017

BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.

Trial Locations (1)

70808

Pennington Biomedical Research Center, Baton Rouge

Sponsors

Lead Sponsor

BioKier Inc.
All Listed Sponsors
lead

BioKier Inc.

INDUSTRY